{"entity":{"id":"nct04639986","kind":"trial","name":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","aka":[],"tldr":"A phase 3 trial of Sacituzumab govitecan, Eribulin, Capecitabine, Gemcitabine and Vinorelbine in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.","summary":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC). ClinicalTrials.gov record last updated 2026-02-09: active not recruiting. Enrollment is actual at 331 participants. Primary completion is estimated at 2026-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral Product, Gemcitabine Injection, Vinorelbine injection. Registered primary measures: Progression-free Survival (PFS).","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04639986","url":"https://clinicaltrials.gov/study/NCT04639986"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["sacituzumab-govitecan","eribulin","capecitabine","gemcitabine","vinorelbine"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-02-09: active not recruiting. Enrollment is actual at 331 participants. Primary completion is estimated at 2026-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT04639986","phase":"3","setting":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","sponsor":"Gilead Sciences","participation":[{"nct":"NCT04639986","source":"https://clinicaltrials.gov/study/NCT04639986","fetchedAt":"2026-10-07T16:53:23.898Z","studySha256":"892d8ddbf5e8411d4eb6eb58439c49d6a9e56ddee22c070accbef2d8651723fc","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-02-09","leadSponsor":"Gilead Sciences","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":331,"enrolmentType":"ACTUAL","siteCount":43,"recruitingSiteCount":0,"countries":["China","South Korea","Taiwan"]}],"started":"2020-11-23","startedType":"actual","enrolled":331,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04639986/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}]}}